NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
11 hedge funds and large institutions have $1.79M invested in NeuBase Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.
973% more capital invested
Capital invested by funds: $167K → $1.79M (+$1.63M)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
83% more funds holding
Funds holding: 6 → 11 (+5)
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$1.01M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$128K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$81.8K |
| 4 |
State Street
Boston,
Massachusetts
|
+$76.3K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$73.6K |
Top Sellers
| 1 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
-$24.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Goldman Sachs
New York
| $1.21M | +$1.01M | +372 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $151K | +$128K | +47 | New |
|
|
FNBT
3
FineMark National Bank & Trust
Fort Myers,
Florida
| $97K | -$24.5K | -9 | -23% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $97K | +$81.8K | +30 | New |
|
|
5
State Street
Boston,
Massachusetts
| $92K | +$76.3K | +28 | New |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $87K | +$73.6K | +27 | New |
|
7
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $24K | +$10.9K | +4 | +100% |
|
|
U
8
UBS
Zurich,
Switzerland
| $15K | +$2.73K | +1 | +25% |
|
9
First Manhattan
New York
| $13K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $7K | +$2.73K | +1 | +100% |
|
11
Wells Fargo
San Francisco,
California
| $3K | – | – | – |
|
NBSE Hedge Fund Activity: Q3 2013 in Review
11 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2013, worth a combined $1.79M — up 973% from $167K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NBSE positions and 0 closed out — a net gain of 5 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.01M. The largest seller was FineMark National Bank & Trust, cutting an estimated $24.5K.
- 11 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2013, up from 6 in Q2 2013.
- Funds reported $1.79M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2013, up 973% quarter-over-quarter.
- 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2013 and 0 closed out, a net change of +5 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2013 was Goldman Sachs, an estimated $1.01M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2013 was FineMark National Bank & Trust, an estimated $24.5K sold.
Based on aggregated 13F filings for Q3 2013.